Director at Twist Bioscience (NASDAQ: TWST) sells 500 shares

Q: Who is the insider involved in the latest Twist Bioscience (TWST) Form 4?

The insider is Melissa A. Starovasnik , a director of Twist Bioscience Corp. She reported one open-market sale of Common Stock and, following this transaction, continues to directly own 25,222 shares according to the Form 4 disclosure.

Q: How many Twist Bioscience (TWST) shares were sold and at what price?

The Form 4 reports a sale of 500 shares of Twist Bioscience Common Stock. These shares were sold in the open market at a price of $61.83 per share, as disclosed in the transaction details for the non-derivative security.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Twist Bioscience Corp director Melissa A. Starovasnik sold shares in a planned transaction. On April 27, 2026, she completed an open-market sale of 500 shares of Common Stock at $61.83 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating it was scheduled in advance. After this transaction, she continues to hold 25,222 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 500 shares ($30,915)

Net Sell 1 txn

Insider Starovasnik Melissa A.

Role null

Sold 500 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$61.83	$31K

Holdings After Transaction: Common Stock — 25,222 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 500 shares Sale price per share: $61.83 per share Shares held after transaction: 25,222 shares +1 more

4 metrics

Shares sold 500 shares Open-market sale of Common Stock on April 27, 2026

Sale price per share $61.83 per share Price for the 500-share open-market sale

Shares held after transaction 25,222 shares Direct ownership following the reported sale

Net shares sold 500 shares Net change in buy/sell activity in this Form 4

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, non-derivative

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type: non-derivative"

Form 4 Insider Transactions: What Each Field Means →

04/29/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Starovasnik Melissa A.

(Last)

(First)

(Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BOULEVARD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/27/2026		S⁽¹⁾		500	D	$61.83	25,222	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on November 22, 2025.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Melissa A. Starovasnik	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Twist Bioscience (TWST) report in this Form 4?

The filing shows director Melissa A. Starovasnik sold 500 shares of Twist Bioscience Common Stock. The open-market sale occurred at $61.83 per share and was reported as a non-derivative transaction, meaning it involved regular shares rather than options or other derivatives.

Who is the insider involved in the latest Twist Bioscience (TWST) Form 4?

The insider is Melissa A. Starovasnik, a director of Twist Bioscience Corp. She reported one open-market sale of Common Stock and, following this transaction, continues to directly own 25,222 shares according to the Form 4 disclosure.

How many Twist Bioscience (TWST) shares were sold and at what price?

The Form 4 reports a sale of 500 shares of Twist Bioscience Common Stock. These shares were sold in the open market at a price of $61.83 per share, as disclosed in the transaction details for the non-derivative security.

How many Twist Bioscience (TWST) shares does the director hold after the sale?

After the reported transaction, director Melissa A. Starovasnik directly holds 25,222 shares of Twist Bioscience Common Stock. This post-transaction holding is explicitly listed in the Form 4 as the total number of shares beneficially owned following the sale.

Was the Twist Bioscience (TWST) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote explains the transaction was effected under a Rule 10b5-1 trading plan. The plan was previously adopted by the reporting person on November 22, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.

Does the Form 4 for Twist Bioscience (TWST) include any derivative transactions?

No derivative securities are shown in this Form 4. The transaction involves only non-derivative Common Stock, and the derivativeSummary section is empty, indicating there were no option exercises, conversions, or other derivative-related transactions reported.